Purple Biotech Ltd. (PPBT) stock
Close on Nov 11, 2026Market cap $1.38MP/E 0.0Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $1.38M
- P/E ratio
- 0.0
- Price to sales
- –
- Price to book
- 0.14
- Dividend yield
- –
- Free cash flow yield
- -408.63%
Fundamentals
- Net income
- -$26.39M
- EPS, diluted
- $0.03
- Free cash flow
- -$5.66M
Trading
- Previous close
- $1.34
- Open
- $1.33
- Day's range
- $1.28 – $1.49
- Volume
- 20,257
- Average volume (20 days)
- 28,261
- Beta (5 years)
- 0.76
- 52-week range
- $0.91 – $8.90
- RSI (14 days)
- 64.3
- Volatility (1 year)
- 89.3%
- Relative volume
- 0.02×
- WACC
- 8.7%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PPBT | S&P 500 | Difference | PPBT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.0% | -2.4% | +14.4 pts | ||
| 3 months | -3.9% | -1.2% | −2.7 pts | ||
| Year to date | -77.3% | +12.3% | −89.6 pts | ||
| 1 year | -82.0% | +12.4% | −94.5 pts | ||
| 3 years | -99.3% | +78.8% | −178.1 pts | -81.1% | +21.4% |
| 5 years | -99.8% | +75.2% | −175.0 pts | -72.1% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -57.2% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Purple Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Purple Biotech
Pharmaceutical Preparations
Purple Biotech Ltd. is a clinical-stage biotechnology company engaged in the research, development, and commercialization of oncology treatments. Its product pipeline features CAPTN-3, a preclinical tri-specific antibody platform with lead candidates IM1240 and IM1305, as well as two clinical-stage oncology drug candidates, CM24 and NT219. The company focuses on developing these experimental therapies for cancer patients and potential biopharmaceutical commercialization partners, while none of its active product candidates are currently approved for marketing or commercial sale.
Company profile, executives and historyPurple Biotech stock: common questions
What is Purple Biotech's stock price?
PPBT closed at $1.49 on Nov 11, 2026, up 11.19% on the day. Over the past 52 weeks it traded between $0.91 and $8.90.
What is Purple Biotech's market cap?
Purple Biotech was worth $1.38M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PPBT's P/E ratio?
PPBT trades at 0.0 times earnings, based on diluted earnings per share of $0.03 over fiscal 2025.
Does Purple Biotech pay a dividend?
No. Purple Biotech has not paid a cash dividend over the last twelve months.
How has PPBT stock performed over the past year?
Including dividends, PPBT returned -82.0% over the past year, against +12.4% for the S&P 500.
Who are Purple Biotech's competitors?
Companies most similar to Purple Biotech by business, industry and size include CNBX, CANF, KZIA, CYDY, IMNM.
See a number that looks wrong?